The role of the core in making an organization great and how we do right by them.
Small organizations are amazing for the impact they can have relative to their size.
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC
Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there a number of risks to biotech over the next 1-2 years out of Washington.
Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment.
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace. CEO’s that I have spoken with are gravitating towards a hybrid model that requires employees to be on site for specific days but not the entire week. This is consistent with a recent PWC survey (Figure 1) suggests that only 21% of employers feel that 5 days a week in the office is required to maintain a strong culture.
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC
I’ve been thinking a lot about growth, and for good reason: Dyne is in the midst of a significant scale-up.
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC